These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37067160)

  • 1. Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options.
    Tuan J; Ogbuagu O
    Expert Rev Anti Infect Ther; 2023 Jun; 21(6):565-570. PubMed ID: 37067160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenacapavir: A first-in-class capsid inhibitor for the treatment of highly treatment-resistant HIV.
    Prather C; Lee A; Yen C
    Am J Health Syst Pharm; 2023 Dec; 80(24):1774-1780. PubMed ID: 37767713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenacapavir: A novel injectable HIV-1 capsid inhibitor.
    Hitchcock AM; Kufel WD; Dwyer KAM; Sidman EF
    Int J Antimicrob Agents; 2024 Jan; 63(1):107009. PubMed ID: 37844807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenacapavir: a first-in-class HIV-1 capsid inhibitor.
    Dvory-Sobol H; Shaik N; Callebaut C; Rhee MS
    Curr Opin HIV AIDS; 2022 Jan; 17(1):15-21. PubMed ID: 34871187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of the novel capsid inhibitor lenacapavir to treat multidrug-resistant HIV: week 52 results of a phase 2/3 trial.
    Ogbuagu O; Segal-Maurer S; Ratanasuwan W; Avihingsanon A; Brinson C; Workowski K; Antinori A; Yazdanpanah Y; Trottier B; Wang H; Margot N; Dvory-Sobol H; Rhee MS; Baeten JM; Molina JM;
    Lancet HIV; 2023 Aug; 10(8):e497-e505. PubMed ID: 37451297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expanding therapeutic options: lenacapavir + bictegravir as a potential treatment for HIV.
    Doan J; Brunzo-Hager S; Satterly B; Cory TJ
    Expert Opin Pharmacother; 2023; 24(18):1949-1956. PubMed ID: 38164956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection.
    Segal-Maurer S; DeJesus E; Stellbrink HJ; Castagna A; Richmond GJ; Sinclair GI; Siripassorn K; Ruane PJ; Berhe M; Wang H; Margot NA; Dvory-Sobol H; Hyland RH; Brainard DM; Rhee MS; Baeten JM; Molina JM;
    N Engl J Med; 2022 May; 386(19):1793-1803. PubMed ID: 35544387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenacapavir and the novel HIV-1 capsid inhibitors: an emerging therapy in the management of multidrug-resistant HIV-1 virus.
    Lee NE; Sutherland RK
    Curr Opin Infect Dis; 2023 Feb; 36(1):15-19. PubMed ID: 36753704
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lenacapavir: A Novel Long-Acting Capsid Inhibitor for HIV.
    Tailor MW; Chahine EB; Koren D; Sherman EM
    Ann Pharmacother; 2024 Feb; 58(2):185-195. PubMed ID: 37138515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial.
    Gupta SK; Berhe M; Crofoot G; Benson P; Ramgopal M; Sims J; McDonald C; Ruane P; Sanchez WE; Scribner A; Liu SY; VanderVeen LA; Dvory-Sobol H; Rhee MS; Baeten JM; Koenig E
    Lancet HIV; 2023 Jan; 10(1):e15-e23. PubMed ID: 36566079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highlights on the Development, Related Patents, and Prospects of Lenacapavir: The First-in-Class HIV-1 Capsid Inhibitor for the Treatment of Multi-Drug-Resistant HIV-1 Infection.
    Dzinamarira T; Almehmadi M; Alsaiari AA; Allahyani M; Aljuaid A; Alsharif A; Khan A; Kamal M; Rabaan AA; Alfaraj AH; AlShehail BM; Alotaibi N; AlShehail SM; Imran M
    Medicina (Kaunas); 2023 May; 59(6):. PubMed ID: 37374245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of an ultra-high performance liquid chromatography-tandem mass spectrometry method for quantifying lenacapavir plasma concentrations: Application to therapeutic monitoring.
    West RE; Oberly PJ; Riddler SA; Nolin TD; Devanathan AS
    J Chromatogr B Analyt Technol Biomed Life Sci; 2023 Nov; 1230():123905. PubMed ID: 37866010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological outlook of Lenacapavir: a novel first-in-class Long-Acting HIV-1 Capsid Inhibitor.
    Di Perri G
    Infez Med; 2023; 31(4):495-499. PubMed ID: 38075416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lenacapavir: First Approval.
    Paik J
    Drugs; 2022 Sep; 82(14):1499-1504. PubMed ID: 36272024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy.
    Cluck DB; Chastain DB; Murray M; Durham SH; Chahine EB; Derrick C; Dumond JB; Hester EK; Jeter SB; Johnson MD; Kilcrease C; Kufel WD; Kwong J; Ladak AF; Patel N; Pérez SE; Poe JB; Bolch C; Thomas I; Asiago-Reddy E; Short WR
    Pharmacotherapy; 2024 May; 44(5):360-382. PubMed ID: 38853601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance Analyses in Highly Treatment-Experienced People With Human Immunodeficiency Virus (HIV) Treated With the Novel Capsid HIV Inhibitor Lenacapavir.
    Margot NA; Naik V; VanderVeen L; Anoshchenko O; Singh R; Dvory-Sobol H; Rhee MS; Callebaut C
    J Infect Dis; 2022 Nov; 226(11):1985-1991. PubMed ID: 36082606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.
    Nka AD; Bouba Y; Teto G; Semengue ENJ; Takou DK; Ngueko AMK; Fabeni L; Carioti L; Armenia D; Pabo W; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Fokam J; Ndjolo A
    J Antimicrob Chemother; 2022 Dec; 78(1):272-275. PubMed ID: 36411257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary.
    Cluck DB; Chastain DB; Murray M; Durham SH; Chahine EB; Derrick C; Dumond JB; Hester EK; Jeter SB; Johnson MD; Kilcrease C; Kufel WD; Kwong J; Ladak AF; Patel N; Pérez SE; Poe JB; Bolch C; Thomas I; Asiago-Reddy E; Short WR
    Pharmacotherapy; 2024 May; 44(5):354-359. PubMed ID: 38853605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants.
    Smith RA; Raugi DN; Nixon RS; Seydi M; Margot NA; Callebaut C; Gottlieb GS;
    J Infect Dis; 2024 May; 229(5):1290-1294. PubMed ID: 38060982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.